

THRU ONLINE FILING

November 14, 2018

BSE Limited  
Phiroze Jeejeebhoy Towers  
27<sup>th</sup> Floor, Dalal Street  
Mumbai 400 023

The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Flr, Plot # C/1  
G Block, Bandra-Kurla Complex,  
Bandra (E), Mumbai 400 051.

Dear Sirs,


Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith our Standalone Unaudited Financial Results along with limited review report of the Company's Auditors for the 2<sup>nd</sup> Quarter and half year ended 30<sup>th</sup> September, 2018 of the financial year 2018-19, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

We are also enclosing herewith a press release issued by the Company in respect of its Q2 FY19 unaudited financial Results.

Kindly note that the Board meeting started at 11.30 a.m. and concluded at 12.55 p.m.

Thanking you

Yours faithfully  
For Ipca Laboratories Limited



Harish P. Kamath  
Corporate Counsel & Company Secretary

Encl: a/a

Ipca Laboratories Ltd.  
[www.ipca.com](http://www.ipca.com)

**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2018**

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sept 30, 2018	June 30, 2018	Sept 30, 2017	Sept 30, 2018	Sept 30, 2017	March 31, 2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	997.82	853.93	864.66	1851.75	1578.08	3219.21
II	Other Income	13.75	13.63	10.63	27.38	16.35	39.54
III	<b>Total Income (I+II)</b>	<b>1011.57</b>	<b>867.56</b>	<b>875.29</b>	<b>1879.13</b>	<b>1594.43</b>	<b>3258.75</b>
IV	Expenses						
	a) Cost of materials consumed	284.43	253.27	218.99	537.70	472.33	923.20
	b) Purchases of stock-in-trade	47.35	35.68	44.15	83.03	71.77	168.30
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.43)	(11.23)	31.89	(29.66)	18.54	20.98
	d) Employee benefits expense	203.77	195.40	187.21	399.17	361.87	712.78
	e) Finance costs	2.38	4.93	6.39	7.31	11.97	24.02
	f) Depreciation and amortisation expense	43.16	44.49	44.05	87.65	87.39	174.36
	g) Other expenses	307.91	266.80	233.02	574.71	482.19	952.31
	<b>Total Expenses (IV)</b>	<b>870.57</b>	<b>789.34</b>	<b>765.70</b>	<b>1659.91</b>	<b>1506.06</b>	<b>2975.95</b>
V	<b>Profit before exceptional items and tax (III-IV)</b>	<b>141.00</b>	<b>78.22</b>	<b>109.59</b>	<b>219.22</b>	<b>88.37</b>	<b>282.80</b>
VI	Exceptional items	-	-	-	-	-	-
VII	<b>Profit before tax (V-VI)</b>	<b>141.00</b>	<b>78.22</b>	<b>109.59</b>	<b>219.22</b>	<b>88.37</b>	<b>282.80</b>
VIII	Tax Expense						
	Current tax	30.41	16.29	19.00	46.70	19.00	60.01
	Short / (Excess) provision of earlier years	(4.31)	(0.68)	-	(4.99)	-	(0.34)
	Deferred tax liability / (asset)	(4.84)	(2.91)	(5.88)	(7.75)	(6.85)	(9.98)
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>119.74</b>	<b>65.52</b>	<b>96.47</b>	<b>185.26</b>	<b>76.22</b>	<b>233.11</b>
X	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss -						
	Actuarial gain/(loss)	0.43	2.84	(0.20)	3.27	0.07	2.30
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.09)	(0.61)	-	(0.70)	-	(0.49)
	B (i) Items that will be reclassified to profit or loss						
	-Exchange difference in translating the financial statement of foreign operation	0.16	(0.15)	(0.08)	0.01	(0.12)	(0.10)
	-Gain/(loss) on cash flow hedge	(2.77)	0.53	(0.28)	(2.24)	2.10	(0.14)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other Comprehensive Income</b>	<b>(2.27)</b>	<b>2.61</b>	<b>(0.56)</b>	<b>0.34</b>	<b>2.05</b>	<b>1.57</b>
XI	<b>Total comprehensive income for the period (IX+X)</b>	<b>117.47</b>	<b>68.13</b>	<b>95.91</b>	<b>185.60</b>	<b>78.27</b>	<b>234.68</b>
XII	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.24	25.27	25.24	25.24
XIII	Other Equity				2847.82	2508.93	2669.71
XIV	<b>Net Worth</b>				<b>2873.09</b>	<b>2534.17</b>	<b>2694.95</b>
XV	Earnings per share (of ₹ 2/- each) (Not annualised):						
	Basic (₹ )	9.48	5.19	7.64	14.66	6.04	18.47
	Diluted (₹ )	9.48	5.19	7.64	14.66	6.04	18.47


SIGNED FOR IDENTIFICATION  
BY   
G. M. KAPADIA & CO.  
MUMBAI.





## STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2018

Particulars	(₹ Crores)	
	Unaudited Sept 30, 2018	Audited March 31, 2018
<b>ASSETS:</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment	1750.08	1816.44
(b) Capital work-in-progress	45.10	42.02
(c) Goodwill	23.61	23.61
(d) Other Intangible assets	16.16	14.56
(e) Intangible assets under development	30.96	31.21
(f) Financial Assets		
(i) Investments in Subsidiary/Joint Venture/Associate	222.05	146.28
(ii) Other investments	-	-
(iii) Loans	112.57	110.45
(iv) Others	3.19	3.17
(g) Other non-current assets	10.96	12.80
<b>(2) Current assets</b>		
(a) Inventories	921.09	873.17
(b) Financial Assets		
(i) Investments	30.06	69.35
(ii) Trade receivables	768.17	594.38
(iii) Cash and cash equivalents	132.62	129.74
(iv) Bank Balance other than (iii) above	1.41	1.29
(v) Loans	2.36	2.14
(vi) Others	93.73	90.76
(c) Current tax assets	-	-
(d) Other current assets	133.83	146.34
<b>Total Assets</b>	<b>4297.95</b>	<b>4107.71</b>
<b>EQUITY AND LIABILITIES:</b>		
<b>Equity</b>		
(a) Equity Share Capital	25.27	25.24
(b) Other Equity	2847.82	2669.71
<b>Liabilities</b>		
<b>(1) Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	197.65	234.01
(ii) Other financial liabilities	-	-
(b) Provisions	26.31	25.88
(c) Deferred tax liabilities (net)	150.91	158.66
(d) Other non-current liabilities	1.56	1.56
<b>(2) Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	270.53	239.04
(ii) Trade payables :		
Due to micro enterprises and small enterprises	2.54	2.19
Due to others	450.31	412.56
(iii) Other financial liabilities	203.25	231.61
(b) Other current liabilities	30.27	30.39
(c) Provisions	74.05	67.21
(d) Current Tax Liabilities (Net)	17.48	9.65
<b>Total Equity and Liabilities</b>	<b>4297.95</b>	<b>4107.71</b>

SIGNED FOR IDENTIFICATION  
BY   
G. M. KAPADIA & CO.  
MUMBAI.




**Notes:**

- 1 The above standalone unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on November 14, 2018.
- 2 The Auditors of the Company have carried out the limited review of the above unaudited financial results.
- 3 During the quarter, the Company's wholly owned overseas subsidiary - Ipca Pharmaceuticals, Inc. USA has acquired 80% share holding of Bayshore Pharmaceuticals, LLC., USA, a company engaged in the sales and marketing of FDA approved generics drug products in the United States of America.
- 4 Effective April 1, 2018, the Company has adopted Ind AS 115 on 'Revenue from Contracts with Customers' using the cumulative catch-up transition method. The adoption of this standard did not have any material impact on the above financial results.
- 5 Revenue from Operations for the quarter ended September 30, 2018, June 30, 2018, September 30, 2017 and half year ended September 30, 2018 are shown net of Goods and Services Tax (GST). Revenue from Operations for the corresponding half year ended September 30, 2017 and for the financial year ended March 31, 2018 includes excise duty upto June 30, 2017. For comparison purposes revenue excluding excise duty is given below :

Sr.No.	Particulars	(₹ Crores)					
		Quarter Ended		Half Year Ended			Year Ended
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
A.	Total Income from operations	997.82	853.93	864.66	1851.75	1578.08	3219.21
B.	Excise Duty on sales (included in other expenses)	-	-	-	-	10.28	10.28
C.	Total Income from operations excluding Excise duty on Sales (A-B)	997.82	853.93	864.66	1851.75	1567.80	3208.93

- 6 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 7 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

SIGNED FOR IDENTIFICATION  
BY   
G. M. KAPADIA & CO.  
MUMBAI.

Place : Mumbai,  
Date : November 14, 2018

By Order of the Board  
For Ipca Laboratories Limited

  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)





**G. M. KAPADIA & CO.**  
(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

**Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of Ipca Laboratories Limited for the Quarter and Half year ended on September 30, 2018 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
**The Board of Directors**  
**Ipca Laboratories Limited**  
Mumbai

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Ipca Laboratories Limited** ("the Company") for the quarter and half year ended on September 30, 2018, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/ 2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For G. M. KAPADIA & CO.**  
Chartered Accountants  
Firm Registration No. 104767W



*Atul Shah*

**Atul Shah**  
Partner

Membership No. 039569

Mumbai  
Dated: November 14, 2018

## PRESS RELEASE

### Ipca Laboratories Q2 FY19 Financial Results

**Mumbai, November 14, 2018:** Ipca Laboratories Limited today announced its unaudited standalone financial results for the second quarter and half year ended 30<sup>th</sup> September, 2018.

#### Key Financials of Q2 FY19

- Net total Income up 16% at Rs. 1011.57 crores.
- Indian formulations income up 10% at Rs. 468.62 crores.
- Exports Income up 22% at Rs. 462 crores.
- EBITDA margin (before Forex loss) @ 21.46% in Q2 FY19 as against @ 18.82% in Q2 FY18
- Net Profit at Rs. 119.74 crores up 24%.

<b>Q2 FY19 at a glance</b>		<b>(Rs. Crores)</b>	
<b>Particulars</b>	<b>Q2 FY19</b>	<b>Q2 FY18</b>	<b>Growth</b>
Net Total Income	1011.57	875.29	16%
Export Income	462.00	380.01	22%
EBITDA before Forex (gain) / loss	217.08	164.71	32%
Forex (gain) / loss	30.54	4.68	-
Finance Cost	2.38	6.39	-63%
Depreciation and Amortisation	43.16	44.05	-2%
Tax Expense	21.26	13.12	62%
Net Profit after tax	119.74	96.47	24%
Earnings per share of Rs. 2/- each (Rs.)	9.48	7.64	24%

<b>Q2 FY19 Revenue break-up</b>		<b>(Rs. Crores)</b>	
<b>Particulars</b>	<b>Q2 FY19</b>	<b>Q2 FY18</b>	<b>Growth</b>
<b><u>Formulations</u></b>			
Domestic	468.62	424.73	10%
<b><u>Exports</u></b>			
Branded	83.24	91.10	-9%
Institutional	43.80	21.95	100%
Generics	161.23	121.02	33%
<b>Total Formulations</b>	<b>756.89</b>	<b>658.80</b>	<b>15%</b>
<b><u>APIs</u></b>			
Domestic	51.42	47.85	7%
Exports	173.73	145.94	19%
<b>Total APIs</b>	<b>225.15</b>	<b>193.79</b>	<b>16%</b>
<b>Grand Total</b>	<b>982.04</b>	<b>852.59</b>	<b>15%</b>





**Key Financials of H1 FY19**


- Net Total Income up 18% at Rs. 1879.13 crores.
- Indian formulations income up 21% at Rs. 869.56 crores.
- Exports Income up 12% at Rs. 843.73 crores.
- EBITDA margin (before Forex loss) @ 19.66% in H1 FY19 as against @ 11.80% in H1 FY18
- Net Profit at Rs. 185.26 crores up 143%.

H1 FY19 at a glance		(Rs. Crores)	
Particulars	H1 FY19	H1 FY18	Growth
Net Total Income	1879.13	1594.43	18%
Export Income	843.73	751.13	12%
EBITDA before Forex (gain) / loss	369.50	188.08	96%
Forex (gain) / loss	55.32	0.35	-
Finance Cost	7.31	11.97	-39%
Depreciation and Amortisation	87.65	87.39	-
Tax Expense	33.96	12.15	180%
Net Profit after tax	185.26	76.22	143%
Earnings per share of Rs. 2/- each (Rs.)	14.66	6.04	143%

H1 FY19 Revenue break-up		(Rs. Crores)	
Particulars	H1 FY19	H1 FY18	Growth
<b>Formulations</b>			
Domestic	869.56	719.73	21%
<b>Exports</b>			
Branded	161.77	170.12	-5%
Institutional	85.28	56.84	50%
Generics	265.22	242.97	9%
<b>Total Formulations</b>	<b>1381.83</b>	<b>1189.66</b>	<b>16%</b>
<b>APIs</b>			
Domestic	111.44	84.06	33%
Exports	331.46	281.20	18%
<b>Total APIs</b>	<b>442.90</b>	<b>365.26</b>	<b>21%</b>
<b>Grand Total</b>	<b>1824.73</b>	<b>1554.92</b>	<b>17%</b>

**About Ipca Laboratories:**

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 45% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.

  
 Premchand Godha  
 Chairman & Managing Director



Encl: Unaudited Standalone Financial Results

**Contact Information:**

Harish P. Kamath, Corporate Counsel & Company Secretary at [harish.kamath@ipca.com](mailto:harish.kamath@ipca.com) or on +91-22- 6210 6056

ipca laboratories Ltd.  
[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 India | T: +91 22 6647 4444 F: +91 22 2868 6954

E: [ipca@ipca.com](mailto:ipca@ipca.com) CIN: L24239MH1949PLC007837